tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Sheiner PA et al. | Acute renal failure associated with the use of ibuprofen in two liver transplant recipients on FK506. | 1994 | Transplantation | pmid:7513099 |
| Therapondos G et al. | Cardiac hypertrophy in liver transplant recipients: tacrolimus, cyclosporine or both? | 2003 | Transplantation | pmid:12883220 |
| Ogunseinde BA et al. | A case of tacrolimus (FK506)-induced pancreatitis and fatality 2 years postcadaveric renal transplant. | 2003 | Transplantation | pmid:12883222 |
| Thomas J et al. | The immunosuppressive action of FK506. In vitro induction of allogeneic unresponsiveness in human CTL precursors. | 1990 | Transplantation | pmid:1689518 |
| Burroughs TE et al. | Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. | 2007 | Transplantation | pmid:17452891 |
| Migita K et al. | FK506 markedly enhances apoptosis of antigen-stimulated peripheral T cells by down-regulation of Bcl-xL. | 1999 | Transplantation | pmid:10532544 |
| Leroy-Matheron C et al. | Inhibitor against coagulation factor V after liver transplantation. | 1999 | Transplantation | pmid:10532550 |
| Méndez A et al. | Pharmacokinetic study of conversion from tacrolimus twice-daily to tacrolimus once-daily in stable lung transplantation. | 2014 | Transplantation | pmid:24492423 |
| Boleslawski E et al. | Defective inhibition of peripheral CD8+ T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection. | 2004 | Transplantation | pmid:15223897 |
| Hougardy JM et al. | The once-daily formulation of tacrolimus: a step forward in kidney transplantation? | 2012 | Transplantation | pmid:22234346 |
| Bilolo KK et al. | Synergistic effects of malononitrilamides (FK778, FK779) with tacrolimus (FK506) in prevention of acute heart and kidney allograft rejection and reversal of ongoing heart allograft rejection in the rat. | 2003 | Transplantation | pmid:12811249 |
| Morrissey PE et al. | Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria. | 1997 | Transplantation | pmid:9089224 |
| Kiuchi T et al. | A hepatic graft tuberculosis transmitted from a living-related donor. | 1997 | Transplantation | pmid:9089234 |
| Jeske HC et al. | Gemcitabine with cyclosporine or with tacrolimus exerts a synergistic effect and induces tolerance in the rat. | 2003 | Transplantation | pmid:14557751 |
| Karlsson H and Nässberger L | FK506 suppresses the mitogen-induced increase in lymphocyte adhesiveness to endothelial cells, but does not affect endothelial cell activation in response to inflammatory stimuli. | 1997 | Transplantation | pmid:9355847 |
| Reding R et al. | Conversion from cyclosporine to FK506 for salvage of immunocompromised pediatric liver allografts. Efficacy, toxicity, and dose regimen in 23 children. | 1994 | Transplantation | pmid:7507272 |
| Storb R et al. | FK-506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidentical donors. | 1993 | Transplantation | pmid:7692635 |
| Thervet E et al. | Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. | 2003 | Transplantation | pmid:14578760 |
| McDiarmid SV et al. | A comparison of renal function in cyclosporine- and FK-506-treated patients after primary orthotopic liver transplantation. | 1993 | Transplantation | pmid:7692636 |
| Osowski CL et al. | Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. | 1996 | Transplantation | pmid:8610430 |
| Burroughs TE et al. | Increasing incidence of new-onset diabetes after transplant among pediatric renal transplant patients. | 2009 | Transplantation | pmid:19667939 |
| Mittal SK et al. | Increased interleukin-10 production without expansion of CD4+CD25+ T-regulatory cells in early stable renal transplant patients on calcineurin inhibitors. | 2009 | Transplantation | pmid:19667950 |
| Saliba F et al. | Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study. | 2016 | Transplantation | pmid:27454919 |
| Kung L and Halloran PF | Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations. | 2000 | Transplantation | pmid:10933159 |
| Beatty PR et al. | Effect of cyclosporine and tacrolimus on the growth of Epstein-Barr virus-transformed B-cell lines. | 1998 | Transplantation | pmid:9603175 |
| Maes BD et al. | Differences in gastric motor activity in renal transplant recipients treated with FK-506 versus cyclosporine. | 1999 | Transplantation | pmid:10589943 |
| Gruber SA et al. | Initial results of solitary pancreas transplants performed without regard to donor/recipient HLA mismatching. | 2000 | Transplantation | pmid:10933170 |
| Shapiro R et al. | Alopecia as a consequence of tacrolimus therapy. | 1998 | Transplantation | pmid:9603186 |
| Shapiro AM et al. | Defining optimal immunosuppression for islet transplantation based on reduced diabetogenicity in canine islet autografts. | 2002 | Transplantation | pmid:12490784 |
| Lang T et al. | Production of IL-4 and IL-10 does not lead to immune quiescence in vascularized human organ grafts. | 1996 | Transplantation | pmid:8824477 |
| Mehra MR et al. | Ethnic disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil-based immunosuppression. | 2002 | Transplantation | pmid:12490790 |
| Shapiro R et al. | Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. | 2008 | Transplantation | pmid:18431232 |
| Augustine JJ et al. | Improved renal function after conversion from tacrolimus/sirolimus to tacrolimus/mycophenolate mofetil in kidney transplant recipients. | 2006 | Transplantation | pmid:16612276 |
| Meier M et al. | Slowing the progression of chronic allograft nephropathy by conversion from cyclosporine to tacrolimus: a randomized controlled trial. | 2006 | Transplantation | pmid:16612281 |
| Tan HP et al. | Pediatric living donor kidney transplantation under alemtuzumab pretreatment and tacrolimus monotherapy: 4-year experience. | 2008 | Transplantation | pmid:19104412 |
| de Fijter JW | Tacrolimus dosing in mycophenolate-treated patients--can we get away with less? | 2011 | Transplantation | pmid:21654351 |
| Brunet M et al. | Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. | 2006 | Transplantation | pmid:16495801 |
| Kessler L et al. | Tacrolimus-associated optic neuropathy after pancreatic islet transplantation using a sirolimus/tacrolimus immunosuppressive regimen. | 2006 | Transplantation | pmid:16495816 |
| Meiser BM | The best dosing for initial tacrolimus application is trough level adapted! | 2005 | Transplantation | pmid:15714162 |
| Taylor-Fishwick DA et al. | Evidence that rapamycin has differential effects of IL-4 function. Multiple IL-4 signaling pathways and implications for in vivo use. | 1993 | Transplantation | pmid:7689258 |
| Guasch A et al. | Assessment of efficacy and safety of FK778 in comparison with standard care in renal transplant recipients with untreated BK nephropathy. | 2010 | Transplantation | pmid:20811320 |
| Ciancio G et al. | A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. | 2004 | Transplantation | pmid:14742990 |
| Azzola A et al. | Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. | 2004 | Transplantation | pmid:14742993 |
| van Hooff JP et al. | Tacrolimus and posttransplant diabetes mellitus in renal transplantation. | 2005 | Transplantation | pmid:15940032 |
| Wang X et al. | Immunosuppression with a combination of pg490-88 and a subtherapeutic dose of FK506 in a canine renal allograft model. | 2005 | Transplantation | pmid:15940043 |
| Nankivell BJ et al. | Oral cyclosporine but not tacrolimus reduces renal transplant blood flow. | 2004 | Transplantation | pmid:15167607 |
| Hewitt CW and Black KS | Comparative studies of FK506 with cyclosporine. | 1988 | Transplantation | pmid:2458644 |
| Ellis D et al. | Phospholipase-C and Na-K ATPase activation by cyclosporine and FK506 in LLC-PK1, cells. Possible implications in blood pressure regulation. | 1991 | Transplantation | pmid:1714643 |
| Rezeig MA et al. | Kaposi's sarcoma in liver transplant recipients on FK506: two case reports. | 1997 | Transplantation | pmid:9175820 |
| Mor E et al. | Reversal of gastrointestinal toxicity associated with long-term FK506 immunosuppression by conversion to cyclosporine in liver transplant recipients. | 1994 | Transplantation | pmid:7513098 |